icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Real-World Effectiveness of Sofosbuvir and Ledipasvir/Sofosbuvir Based Regimens in Hepatitis C Virus Genotype 3 Infection Within National Hepatitis C Elimination Program in the Country of Georgia
 
 
    Reported by Jules Levin
AASLD Liver Meeting Oct 20-24 2017, Washington DC 
 
Tengiz Tsertsvadze,1,2 Nikoloz Chkhartishvili,1 Akaki Abutidze,1 Lali Sharvadze,2,3 Vakhtang Kerashvili,1 George Kamkamidze,4 Mamuka Zakalashvili,5 Lia Gvinjilia,6 Muazzam Nasrullah,7 Amiran Gamkrelidze,8 Valeri Kvaratskhelia,9 Stefan Zeuzem, 10 Sanjeev Arora,11 Karla Thornton, 11 Nezam Afdhal,12 Francisco Averhoff7
 
Infectious Diseases, AIDS and Clinical Immunology Research Center 1Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia; 2Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia; 3Hepatology Clinic Hepa, Tbilisi, Georgia; 4NeoLab, Tbilisi, Georgia; 5Mrcheveli, Tbilisi, Georgia; 6CDC Foundation, Tbilisi, Georgia; 7Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC, Atlanta, GA, USA; 8National Center for Disease Control and Public Health, Tbilisi, Georgia; 9Ministry of Labour, Health and Social Affairs of Georgia, Tbilisi, Georgia; 10 Goethe University Hospital, Frankfurt, Germany; 11 University of New Mexico, Albuquerque, NM, USA; 12Harvard Medical School, Boston, MA, USA

1106171

1106172

1106173

1106174